Literature DB >> 6287893

Ketoconazole blocks adrenal steroid synthesis.

A Pont, P L Williams, D S Loose, D Feldman, R E Reitz, C Bochra, D A Stevens.   

Abstract

Ketoconazole, a broad-spectrum, antifungal drug that is administered orally, has been shown to inhibit sterol synthesis in fungi. When gynecomastia developed in some patients taking this drug, we investigated the effects of ketoconazole on steroid synthesis in humans and in isolated adrenal cells from rats. In healthy humans, the cortisol response to adrenocorticotropic hormone was significantly blunted 4 hours after a 400-mg or 600-mg dose. The inhibition persisted for up to 8 hours and was absent by 16 hours. This finding indicated that adrenal androgen response was reduced. Easily achieved therapeutic concentrations of ketoconazole virtually eliminated corticosterone production by isolated adrenal cells from rats. Although ketoconazole at currently used doses has never been documented to cause clinical hypoadrenalism, caution is urged in high- or multiple-dose trials. The drug may prove useful as an agent to block steroid synthesis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6287893     DOI: 10.7326/0003-4819-97-3-370

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  75 in total

Review 1.  A history of prostate cancer treatment.

Authors:  Samuel R Denmeade; John T Isaacs
Journal:  Nat Rev Cancer       Date:  2002-05       Impact factor: 60.716

Review 2.  In vitro models for studying toxicity of antifungal agents.

Authors:  V Joly; J Bolard; P Yeni
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

Review 3.  Adverse drug reactions to systemic antifungals. Prevention and management.

Authors:  J R Perfect; M H Lindsay; R H Drew
Journal:  Drug Saf       Date:  1992 Sep-Oct       Impact factor: 5.606

4.  Diagnosis and treatment of Cushing's syndrome. Cushing's syndrome: current clinical problems, symposium. Padova, October 19-20, 1990.

Authors: 
Journal:  J Endocrinol Invest       Date:  1992-03       Impact factor: 4.256

5.  High-dose itraconazole in the treatment of severe mycoses.

Authors:  P K Sharkey; M G Rinaldi; J F Dunn; T C Hardin; R J Fetchick; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

Review 6.  CYP17 inhibitors for prostate cancer therapy.

Authors:  Tadas S Vasaitis; Robert D Bruno; Vincent C O Njar
Journal:  J Steroid Biochem Mol Biol       Date:  2010-11-17       Impact factor: 4.292

7.  Improved responsiveness of PCOS patients to clomiphene after CYP17a inhibitor.

Authors:  H Ali Hassan; D El-Gezeiry; T M Nafaa; I Baghdady
Journal:  J Assist Reprod Genet       Date:  2001-11       Impact factor: 3.412

Review 8.  Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.

Authors:  Irina Veytsman; Lynnette Nieman; Tito Fojo
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

9.  Ketoconazole blocks bile acid synthesis in hepatocyte monolayer cultures and in vivo in rat by inhibiting cholesterol 7 alpha-hydroxylase.

Authors:  H M Princen; C M Huijsmans; F Kuipers; R J Vonk; H J Kempen
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

10.  Cytotoxicity of ketoconazole in malignant cell lines.

Authors:  C F Rochlitz; L E Damon; M B Russi; A Geddes; E C Cadman
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.